Cytodyn Inc (CYDY)

[BlackDoggie]

So, you've confirmed for me that it would be "expensive" and likely "disastrous". I understand that it's a different skill set, and obviously other parties would have to be brought in. I don't think anyone was under the impression that Pourhassan or Pestell would be running a sales team. Could you provide more color around why, say, $20mm up front this year (from capital in excess of what would be required to get the BLA and the 510k through, for example), followed by minimal revenues of $50-100mm (scaling back market penetration for combo by 90% and not even considering the diagnostic test) in 2020, would not be enough to build a sales force? I understand that some aspects of distribution would be outsourced, and I probably should have left that out of earlier comments. Also, the excess capital number is roughed out. If the sticking point is $5-10mm either way, I don't consider that insurmountable. If it's an order of magnitude off, that's a different story.

I'm trying to understand why this outcome, although clearly slower and more dilutive on the front end, would be so "disastrous" as compared to potentially handing 80% of revenue (or more, I'm roughing out numbers based on other partnership deals I've researched) to BP for doing nothing in the development stage, just so we can get a deal done. So far, I've heard nothing to provide any support for how "expensive" and "disastrous" this would be.